Home/Investors/Longitude Capital

Longitude Capital

Biotech Investor · 3 portfolio companies

Portfolio

3

Combined Value

$6.6B

Focus Areas

3

Top Stage

Phase 3

Investment Focus

Oncology Urologic Oncology Ophthalmology

Portfolio Companies

Company	Stage	Valuation	Focus
CG Oncology	Phase 3	$5.5B	Oncology, Urologic Oncology
CytomX Therapeutics	Phase 1	$757.3M	Oncology
LENZ Therapeutics	Phase 3	$327.9M	Ophthalmology

Frequent Co-Investors

Public market investors1 shared Decheng Capital1 shared Ally Bridge Group (founding member connection)1 shared Foresite Capital1 shared RA Capital Management1 shared Versant Ventures1 shared Sectoral Asset Management1 shared PIPE Investors1 shared